Evidence map›Paper›PMID 41276708›Full record

ArticleDiscover oncology2025

Integrated multi-omics analysis identifies key biomarkers associated with post-translational modifications and RNA methylation in clear cell renal cell carcinoma.

Taisen Pang, Yongzhi He, Jie Liao, Xiuwang Wei

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Taisen Pang *Department of Urology I, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Yongzhi He *Department of Urology I, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Jie Liao *Department of Urology I, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Xiuwang WeiDepartment of Urology I, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. Dr.wxw@163.com.

Funding

The Development, Promotion, and Application Project of Appropriate Medical and Healthcare Technologies of Guangxi S2022022
6 · The paper itself

Abstract

backgroundThis study aimed to identify clinically relevant molecular signatures and biomarkers associated with post-translational modifications (PTMs) and RNA methylation in clear cell renal cell carcinoma (ccRCC) by integrating multi-omics data to elucidate tumorigenesis mechanisms and tumor microenvironment dynamics for potential diagnostic and therapeutic advancements.

methodsWe analyzed bulk RNA-sequencing data from five GEO datasets, GSE16449, GSE46699, GSE53000, GSE53757, and GSE66272, with batch-effect correction using the sva package and single-cell RNA-seq data processed via Seurat v4 with Harmony integration. Differential expression analysis using limma identified PTM- and methylation-related gene signatures. Functional enrichment using clusterProfiler and Weighted Gene Co-expression Network Analysis (WGCNA) revealed key modules linked to 20 PTM types and four RNA methylation patterns, m1A, m5C, m6A, and m7G. Machine learning using LASSO, SVM, and Random Forest, along with SHAP-based random forest modeling, selected and evaluated biomarkers. Immune infiltration was assessed via ssGSEA, and consensus clustering defined molecular subtypes. Statistical analyses using Wilcoxon and Kruskal-Wallis tests with FDR correction ensured robustness.

resultsWe identified 2,779 differentially expressed genes, including 14 significant PTM and methylation signatures including 11 PTMs, 3 methylation types, enriched in PI3K-Akt signaling and immune response pathways. WGCNA revealed four disease-associated modules tied to PTMs and RNA methylation. Single-cell analysis delineated 16 cell types, with T cells dominant in tumors and enhanced cell-cell interactions in high-modification groups. Machine learning identified PDIA3, STT3A, and USP4 as core biomarkers, with SHAP confirming STT3A's predictive strength. Biomarkers showed elevated expression in ccRCC, correlating with dendritic and T cell infiltration. Consensus clustering defined two subtypes: C2 exhibited higher PTM/methylation-related gene expression, oncogenic pathway enrichment, and lower immune infiltration compared to C1.

conclusionThis integrative multi-omics framework identifies PDIA3, STT3A, and USP4 as key biomarkers linked to PTMs and RNA methylation, delineating two molecular subtypes. These findings enhance understanding of ccRCC's molecular and immune landscape, offering insights for improved diagnostic and therapeutic strategie.

Indexed as

BiomarkersClear cell renal cell carcinomaMulti-OmicsPost-Translational modificationsRNA methylation

Identifiers

PMID41276708
PMCPMC12748336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.